What happened with SCLX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Scilex Holding Company sells prescription medicines to U.S. distributors and pharmacies for patients who need pain treatment without opioids. Most revenue comes from ZTlido, a lidocaine topical system for nerve pain following shingles. It also sells ELYXYB, an oral solution for acute migraine in adults, and GLOPERBA, liquid colchicine used to prevent painful gout flares in adults; both remain in early commercialization.
Scilex acquires or licenses product rights and uses outside manufacturers rather than making the medicines itself. ZTlido depends exclusively on Oishi Koseido and Itochu Chemical Frontier for licensed technology and supply, with Oishi manufacturing it in Japan. Cardinal Health 105 is the sole U.S. logistics provider for all three marketed products. Sales depend on doctors prescribing the medicines and insurers and other payors providing coverage and adequate reimbursement. FDA rules restrict promotion to approved uses. Scilex also develops treatments including SEMDEXA, an injectable gel for sciatica, but these candidates need regulatory approval before they can be marketed.
Separately, Scilex holds cryptocurrency as part of a treasury investment strategy. These assets do not pay interest; the strategy seeks cash from price appreciation or other income-generating activities, potentially including staking. This is distinct from its medicine-sales business.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Scilex’s product revenue depends chiefly on ZTlido demand and exclusive supply from Japan’s Oishi Koseido and Itochu Chemical Frontier, neither of which appears on this list.
Teva sells generic lidocaine patches that compete directly with ZTlido, Scilex’s largest source of product revenue. Watch Teva’s lidocaine patch business rather than its overall drug sales for competition facing Scilex’s core product.
Scilex relies on Lifecore Biomedical to make clinical-trial supplies of SEMDEXA, its injectable sciatica treatment, and plans to use it for commercial production if approval comes. Scilex pays Lifecore for development and trial-material manufacturing; progress toward commercial production matters for this still-unapproved treatment, not current ZTlido sales.
Datavault AI matters to Scilex’s cash flow: Scilex invested $150 million in Bitcoin for equity and received $39.6 million from selling Datavault shares in 2025. Datavault licenses wireless audio technology, but its tie to Scilex also runs through customer payments—Scilex accounted for 26% of its 2025 net revenue.
Collegium Pharmaceutical markets prescription pain medicines to practices that also choose Scilex’s non-opioid treatments, though the drugs serve different indications and treatment roles. Collegium primarily sells to wholesalers; its pain-medicine sales, rather than its ADHD business, are the relevant comparison for Scilex.
Lifecore Biomedical, Inc. earningsLFCR
Lifecore Biomedical’s report will show how its work making trial supplies for Scilex’s unapproved sciatica treatment SEMDEXA, and preparing for possible commercial production, is progressing.
Look for Lifecore’s comments on development work and trial-material manufacturing, and whether it describes progress toward commercial production. Progress would support Scilex’s path to advancing SEMDEXA trials and arranging supply if the treatment is approved; delays or manufacturing problems would put that path at risk. SEMDEXA is still unapproved, so progress would not mean it is ready to sell.
Teva Pharmaceutical Industries Limited earningsTEVA
Teva’s report will show whether its generic lidocaine-patch business is gaining ground against Scilex’s core product, ZTlido.
Focus on Teva’s lidocaine-patch business, not its overall drug sales. If that business strengthens, generic products competing for patients and prescriptions with ZTlido are gaining traction, increasing pressure on Scilex’s core product; if it weakens, the report offers less evidence of growing generic competition, but does not establish that ZTlido sales will rise.
Datavault AI Inc. earningsDVLT
Datavault AI’s report will show how its revenue and ability to pay are changing, relevant to the contract revenue Scilex records from Datavault as a customer.
Watch Datavault AI’s revenue and any disclosures about payments or cash pressure. Growing revenue alongside signs it can pay would make Scilex’s contract revenue from this customer look more sustainable; weaker revenue or payment strain would make that income less certain. Datavault AI’s results alone cannot confirm that Scilex has received payment.
Scilex Holding Company earningsThis company
Scilex’s report will show whether sales of ZTlido, its main revenue source, are stabilizing and whether its other products can help make up the shortfall.
Start with ZTlido net sales and sales volume, then see whether ELYXYB and GLOPERBA sales are growing. Stabilizing ZTlido sales alongside growth in the other products would show that demand is no longer resting on one product alone; continued ZTlido declines without an offset would mean the revenue base is still shrinking. Cash and financing disclosures will show whether Scilex can keep funding operations and commercialization.
